Lantern Pharma Secures European Patent for AI-Developed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property rights in the U.S. and Japan, enhancing the company's global commercialization strategy. LP-284, developed through Lantern’s innovative RADR(R) AI platform, is currently in Phase 1 trials and has been granted Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL). Targeting a lucrative $4 billion global market, LP-284's development underscores Lantern Pharma's commitment to leveraging artificial intelligence to revolutionize oncology drug discovery and development, offering hope for faster, more cost-effective treatments.

For more details, the full press release can be accessed here. Lantern Pharma stands at the forefront of AI-driven oncology research, with its RADR(R) platform utilizing over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms to accelerate drug development. The company's approach has significantly reduced the time and cost associated with bringing new therapies to market, with programs advancing from AI insights to clinical trials in just 2-3 years at approximately $2.5 million per program. This breakthrough not only highlights Lantern Pharma's potential for strategic partnerships but also its role in transforming cancer treatment paradigms.